Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday
by Amy Steele · The Cerbat GemPuma Biotechnology (NASDAQ:PBYI – Get Free Report) is expected to be releasing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Puma Biotechnology to post earnings of ($0.13) per share and revenue of $42.00 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.
Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.24 by $0.02. Puma Biotechnology had a net margin of 13.62% and a return on equity of 27.80%. The business had revenue of $75.50 million during the quarter, compared to analyst estimates of $68.60 million. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Puma Biotechnology Stock Down 2.4%
Shares of Puma Biotechnology stock traded down $0.18 on Tuesday, reaching $7.35. The stock had a trading volume of 416,399 shares, compared to its average volume of 372,681. The company has a 50 day moving average price of $6.80 and a 200 day moving average price of $6.15. Puma Biotechnology has a 1 year low of $2.85 and a 1 year high of $7.90. The stock has a market capitalization of $374.06 million, a P/E ratio of 12.05 and a beta of 1.24.
Analyst Ratings Changes
PBYI has been the subject of a number of analyst reports. Wall Street Zen raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 21st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Puma Biotechnology in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Puma Biotechnology currently has a consensus rating of “Hold”.
View Our Latest Stock Report on Puma Biotechnology
Hedge Funds Weigh In On Puma Biotechnology
Several hedge funds have recently modified their holdings of PBYI. AQR Capital Management LLC boosted its stake in Puma Biotechnology by 366.5% in the 1st quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 39,641 shares in the last quarter. Brooklyn Investment Group acquired a new position in Puma Biotechnology during the 3rd quarter valued at approximately $146,000. MetLife Investment Management LLC increased its stake in Puma Biotechnology by 67.8% during the 4th quarter. MetLife Investment Management LLC now owns 24,412 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 9,867 shares in the last quarter. Brandywine Global Investment Management LLC purchased a new position in shares of Puma Biotechnology in the fourth quarter worth $130,000. Finally, Heron Bay Capital Management acquired a new stake in shares of Puma Biotechnology during the fourth quarter worth $119,000. Institutional investors and hedge funds own 61.29% of the company’s stock.
About Puma Biotechnology
Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.
The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.